Life sciences faces significant disruption. Companies need to demonstrate value from therapies; there is a shift from treatment to prevention and cure; patients are becoming powerful consumers thanks to greater digital access to information. Meanwhile, technology giants are moving into healthcare at a growing pace.
COVID-19 has accelerated many of these trends and placed unprecedented pressure on areas such as vaccine development.
Our UK life sciences specialists bring practical, in-depth experience to consumer health, medical devices, diagnostics and biopharma companies. We have worked across more than a dozen therapeutic areas, including immunology, HIV and oncology. Our global network of 4,000 life sciences professionals have supported all of the top 25 life sciences organisations, and shares regular insights on trends, drivers and key issues.
We provide an end-to-end solution for life sciences. We can help you improve commercial capabilities and identify growth opportunities, transform operations, protect business or provide tax advice, leveraging our digital, technology and data analytics capabilities to enhance competitive advantage.
Hilary Thomas, KPMG UK’s Chief Medical Adviser, looks at why collaboration is at the heart of developing a COVID-19 vaccine and distributing it.
Collaboration is at the heart of developing and distributing a global COVID-19 vaccine.